key: cord-1054183-i3dweqoq authors: Morris, Lorna; Nisim-Eliraz, Einat; Schouten, Iftach; Bergey, François; Dyer, Nigel; Momiji, Hiroshi; Nir, Eilam; Marsiano, Noga; Tezerji, Raheleh Sheibani; Yagel, Simcha; Rosenstiel, Philip; Rand, David; dos Santos, Vitor A.P. Martins; Shpigel, Nahum Y. title: Hyperinflammation evokes different antiviral TMPRSS2 and ADAM17 expression responses in human gut xenograft versus host mouse gut although overall genomic responses are similar date: 2021-05-10 journal: bioRxiv DOI: 10.1101/2021.05.09.443289 sha: 9d8fa196324bf5b45806174320ea97906010fd4a doc_id: 1054183 cord_uid: i3dweqoq The global spread of the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the pandemic outbreak of coronavirus disease 2019 (COVID-19), an inflammatory disease that is primarily affecting the respiratory system. However, gastrointestinal symptoms in COVID-19 patients suggests that the gut may present another viral target organ. Disease development and severity is dependent on viral interaction with two cell surface human proteins, ACE2 and TMPRSS2, and on antiviral response which may lead to systemic hyperinflammatory syndrome and multiorgan dysfunction. Understanding the host response to SARS-CoV-2 infection and the pathology of the disease will be greatly enhanced by the development of appropriate animal models. Laboratory mice have been the mainstay of therapeutic and vaccine development, however, the virus does not grow in wild type mice and only induced mild disease in transgenic animals expressing human ACE2. As there are known differences between immune response in laboratory mice and humans we evaluated the response of human gut developed as xenografts and host mouse gut following systemic LPS injections as a hyperinflammation model system. The orthologous gene expression levels in the mouse and human gut were highly correlated (Spearman’s rank correlation coefficient: 0.28–0.76) and gene set enrichment analysis of significantly upregulated human and mouse genes revealed that a number of inflammatory and immune response pathways are commonly regulated in the two species. However, species differences were also observed, most importantly, in the inflamed human gut but not in the mouse gut, there was clear upregulation of mRNAs coding for TMPRSS2, ADAM17 and for RIG-I-like receptors, which are involved in the recognition of viruses and in antiviral innate immune response. Moreover, using species-specific immunofluorescence microscopy, we demonstrated the expression and localization of human ACE2 and TMPRSS2 proteins, which are essential elements of the molecular machinery that enables SARS-CoV-2 to infect and replicate in human gut cells. Our findings demonstrate that the intestinal immune response to inflammation in humans and mice are generally very similar. However, certain human-specific diseases, such as COVID-19, can only be successfully studied in an experimental model of human tissue, such as the gut xenograft. The global spread of the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to pandemic outbreak of human coronavirus disease 2019 (COVID- 19) , an influenza-like disease that is primarily affecting the respiratory system. However, COVID-19 patients often present with gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain. suggesting that the intestine may present another viral target organ (1) . Two cell surface proteins; angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) constitute the molecular machinery enabling SARS-CoV-2 to infect and replicate in human cells. However, recent studies suggest that additional host factors such as the membrane protein neuropilin-1 (NRP1) and the proteases furin and metalloproteinase domain 17 (ADAM17) might also be involved in SARS-Cov-2 processing and entry in human cells (2) (3) (4) (5) (6) . Severe COVID-19 disease is often associated with systemic hyperinflammatory syndrome and multiorgan dysfunction reminiscent of sepsis (7) . Understanding the host response to SARS-CoV-2 infection and the pathology of disease will be greatly enhanced by the development of appropriate animal models. Laboratory mice have been the mainstay of therapeutic and vaccine development, however, the virus does not grow in wild type mice and only induced mild disease in transgenic animals expressing human ACE2 (8) . Furthermore, the validity of mice as a model system in translational research was seriously questioned by Seok et al reporting that transcriptional responses in mouse models poorly mimic human inflammatory diseases (9) . However, alternative analysis of the same gene expression data sets was suggested by Takao and Miyakawa (10) and led to a diametrically opposite conclusion that genomic responses in mouse models greatly mimic human inflammatory diseases. For obvious reasons, this study and many current COVID-19 studies were based on comparative transcriptome analysis of blood leukocytes derived from human patients affected by inflammatory conditions compared with the corresponding mouse models. The use of blood leukocytes as surrogates for transcriptome analysis of inaccessible human tissues in patients was criticized by several authors suggesting the use of parenchymal cells of affected organs for comparative transcriptome analysis in inflammatory conditions (11, 12) . Nevertheless, most of our understanding of disease mechanisms and biology in inflamed organs is based on systematic observations in experimental animals and episodic studies of humans; there is a dearth of comparative transcriptomic data about the human and mouse gut in hyperinflammatory conditions. Here we used human gut tissues developed in mice as xenografts to study the expression and localization of SARS-CoV-2 entry mechanisms and whole genome gene expression response in the human gut under hyperinflammatory conditions. We have utilized an experimental platform, first reported by Winter et al in 1991 (13) and refined in our laboratories for study of enteric nervous system (14, 15) , human-specific pathogens (16-18) and IBD (19) (20) (21) (22) . Fetal gut is obtained from pregnancy terminations performed legally at 12-18 weeks gestational age and transplanted subcutaneously in mature SCID mice, where it grows and can be experimentally manipulated over the course of the subsequent several months. Transplanted mice were subjected to systemic LPS, a well-established model of experimental systemic hyperinflammatory disease (23) (24) (25) (26) . Gene expression profiles were analyzed in human gut transplants and host mouse gut originating from normal control and LPS-treated mice. Next, we adopted the strategy and methodology suggested by Takao and Miyakawa (10) and focused on orthologous genes whose expression levels were significantly changed in both human and mouse gut and used Spearman's rank correlation for comparison of interspecies agreement. Further, we utilized the ImmuneSigDB database (27) , a compendium of approximately 5000 gene expression signatures generated by 389 published studies, to compare the functional consequences of gene expression in mouse and human gut transplants and provide insight into both conserved and species-specific transcriptional responses. Gene Set Enrichment Analysis (GSEA) is used to identify functionally related programs of gene expression (20) for differentially expressed genes using different gene sets, for example Gene Ontology or ImmuneSigDB. GSEA enables relatively small changes in gene expression in a large number of genes to be taken into account when exploring changes in cell state. Genes can be ranked according to a variety of metrics, such as their log fold change in expression or a signal-to-noise calculation, using the mean and variance estimates for the expression of each gene (20) . The leading edge genes in a GSEA analysis are the genes whose expression profile drives the GSEA enrichment statistic and thus are those that appear at the top of the ranked list of differentially expressed genes provided to the GSEA algorithm. By systematically comparing the leading edge genes of the enriched gene sets in the mouse and human we defined a gene expression signature consisting of anti-viral response genes that was specific for hyperinflammation in the human gut. Using immunofluorescence microscopy, we first analyzed human fetal gut (Fig. S1 ) and mature human gut xenografts for the expression and cellular localization of ACE2 and TMPRSS2 (Fig. 1) . Here we show that in steady state human gut xenografts ACE2 and TMPRSS2 are exclusively expressed by gut epithelial cells. However, while all gut epithelial cells were highly positive for cytoplasmic TMPRSS2, ACE2 was specifically localized to the apical membranes along the brush borders of villi epithelial cells. The fact that these cells express both ACE2 and TMPRSS2 indicate susceptibility for SARS-CoV-2 infection and suggest that luminal SARS-CoV-2 viral particles will be able to infect the epithelial cells of the human gut transplants. It is now well established that SARS-CoV-2 infection of the gut does not recapitulate the severe disease and pathology inflicted by respiratory infection which is frequently associated by systemic hyperinflammatory immune response. To better understand and compare human and mouse gut response to hyperinflammation, we next used whole-genome transcription analysis of human gut xenografts and host mouse gut hyperinflammatory response to systemic LPS. The differential gene expression between normal and inflamed human gut transplants and between normal and inflamed mouse gut are presented in Fig. 2 and Fig. 3 , respectively. Differential expression (log 2 fold-changes) in septic gut of human and mouse orthologs were compared. First, all significantly changed orthologous genes (P adj -value < 0.05; |log 2 fold-change| >1) in either human or mouse gut were compared using Pearson's correlation coefficient R 2 (Fig. 4) . Non-significant log 2 fold-changes were assigned the value of 1 (log2 = 0 in Fig. 4 ) and are located on the y-axis (for non-significant human genes in Fig. 4 ) or on the x-axis (for non-significant mouse genes in Fig. 4 ). This analysis recapitulated the data analyses performed by Seok et al (9) suggesting poor correlation between the genomic response in septic human and mouse gut ( Fig. 4; Pearson's correlation coefficient R 2 : 0.0025 -0.0724). We compared genes whose expression levels were significantly changed in both human and mouse gut (P adj -value < 0.05; |log 2 fold-change| >1) using Spearman's rank correlation coefficient ρ (Fig. 5 ). Genomic response of significantly expressed orthologous genes in the septic human and mouse gut was highly correlated ( Fig. 5 ; Spearman's rank correlation coefficient: 0.328-0.762; P = 0.0388 to P < 0.0001). Consistently high correlations were observed between gene expression in the mouse gut following high dose LPS treatment (10 mg/kg) and gene expression in the human gut at all LPS dosage levels, showing that a high dose of LPS was required to elicit a response in the mouse gut (10mg/kg), whilst even low doses of LPS (0.1mg/kg) elicited a response in the human gut (Fig. S2 ). Our approach above followed that of Takao and Miyakawa (10) in using the Spearman correlation coefficient rather than the Pearson coefficient. As pointed out in (10) , the Spearman coefficient is a nonparametric approach to identifying a monotone relationship between two sets of data and, unlike the Pearson coefficient, is not based on normality of the data and is generally much more robust. In addition to the better robustness and the non-normality of our data, the Spearman coefficient is also more appropriate to our task which is to determine the strength of any monotone relationship between the two data sets rather than to quantify a linear relationship between them. Thus, given the much greater appropriateness and robustness of the Spearman coefficient our data suggests highly correlated gene expression in response to hyper-inflammation in the mouse and human gut. To probe the functional consequences of the observed gene expression responses to hyper-inflammation and further test the level of correlation we performed GSEA to compare enrichment of functionally related gene sets and the leading edge genes in the mouse and human responses (28) . We reasoned that sub-groups of genes that are co-regulated are likely to represent distinct biological processes or pathways and that comparison of these across mouse and human is another method to address comparability of the transcriptional response to hyper-inflammation. We performed GSEA using the differential expression results at the LPS concentration of 10mg/kg in both human and mouse (compared to the PBS control) as this treatment had the most highly correlated response between orthologs and more differentially expressed genes than at the lower concentrations of LPS ( showed a highly conserved pattern of gene expression in response to sepsis in mouse and human, but also a species-specific response in distinct biological processes. We ranked all significantly differentially expressed orthologous genes (P adj -value <0.05) according to their fold changes (LPS-stimulated vs unstimulated) in each data set (mouse or human) and performed GSEA using the ImmuneSigDB gene sets. The most enriched gene set in our model system of the human gut gene expression originated from a study in which monocytes were isolated from healthy human donors and were treated with either LPS or vehicle and the gene expression profile compared (GSE9988 with ES= 0.835, adjusted p-value =0.0009). This gene set was also highly enriched when we performed the GSEA with our mouse gut differential expression data (ES= 0.800, adjusted pvalue =0.001). This is consistent with the findings of Godec et al, showing that the transcriptional response to sepsis is highly conserved. In both mouse and human gut the majority of the most highly enriched gene sets are from experiments in which monocytes, macrophages or dendritic cells were treated with LPS. These genes sets predominantly contain genes coding for proinflammatory cytokines including C-X-C motif chemokines, interleukins, cell adhesion proteins and regulators of the adaptive and innate immune response. Gene Sets, there are 806 leading edge genes common to both species (Fig. 6D) . We compared the leading edge genes between the enriched gene sets in our mouse and human comparison and calculated the frequency of occurrence of the genes in these enriched Gene Sets. Fig. 6E -F shows the frequency histograms of leading edge gene occurrences ordered either by their frequency in human ( Fig. 6E ) or their frequency in mouse (Fig. 6F ). The symmetrical distribution (Fig. 6E-F) in the mouse and human histogram comparison are indicative of the conserved differential expression in these gene signatures, and also supported by the good correlation in log fold changes (ρ = 0.253, p-value = 2.2e-16 for mouse, ρ = 0.286 p-value = 2.2e-16 for human). There is a higher correlation between the most frequently occurring genes in the enriched Gene Sets (Fig S3) . Scatterplots to compare the log fold changes in human and mouse of the most frequently occurring leading edge genes are also shown in Figure S3A -B, highlighting those genes that are differentially expressed in mouse but not in human. The human genes with log2 fold changes between 0 and 1 are generally not significant (p adj > 0.05) but several of these genes are more highly expressed in mouse (with log2 fold changes between 1 and 5) and are significant. While ectopic and not functional, these gut implants develop characteristic structures of the human gut with extensive vasculature and their structural features are highly similar to those of normal human gut, including mucosal villous epithelium, crypt structures, blood vessels and enteric nervous system. We and others have previously shown that virtually all the cell types that are present in the normal human gut are also present in these xenografts (14, 16-18, 21, 48, 49) . Moreover, the general architecture of the gut appears normal, and the tissue is well-vascularized by a human capillary system that anastomoses to the circulatory system of the murine host. In this, the experimental platform is similar to other examples of development of human tissues (lung, skin and liver) subcutaneously transplanted into SCID mice (46, 50) . Furthermore, we have shown that many human innate and adaptive components of immune system, which have been shown to be already active in fetal gut at the time of transplantation (51) (52) (53) (54) , are present and active in the mature xenograft (20, 21) . Transplanted SCID mice can be further complemented with cellular components of the human adaptive immune system as we have previously reported (19, 20) to investigate human-specific immune response against SARS-CoV-2 in the human gut. Taken together we expect that SARS-CoV-2 administered intraluminally or systemically will readily infect cells of human gut xenografts and that this platform can serve as an experimental model for coronavirus infection and biology. Women undergoing legal terminations of pregnancy gave written, informed consent for use of fetal tissue in this study. Human fetal small bowel 12-18 weeks gestational age was implanted subcutaneously on the dorsum of the mouse as described previously (21) . All surgical procedures were performed in an aseptic working environment in a laminar flow HEPA-filtered hood with isoflurane inhalation anesthesia (1.5 to 2% v/v isofluorane in O2). Before surgery, carprofen (5 mg/kg, Rimadyl, Pfizer Animal health) was administered subcutaneously. The surgical area was shaved and depilated (Nair hair removal cream) and the skin was scrubbed and disinfected with betadine and 70% (v/v) ethanol. After surgery the mice were provided with enrofloxacin-medicated water (Bayer Animal HealthCare AG) for 7 days and were closely monitored once a day for behavior, reactivity, appearance and defecation. Grafts developed in situ for 12-16 weeks prior to manipulation. Histology and Immunofluorescence. As we have previously described (15, 20) , human fetal gut and xenograft tissues were harvested for immunofluorescence staining and microscopic analysis. Transplanted mice were subjected to systemic LPS (from E. coli serotype O55:B5, Sigma, Rehovot, Israel) at 0.1, 1 or 10 mg/kg by intraperitoneal injection. Viability and clinical signs were monitored and scored by visual examination (Fig. S5) . Clinical score was adopted from Bougaki, et al (55) . Four hours after LPS treatment mice were humanely sacrificed, and human gut transplants and mouse ileum were harvested. Full thickness sections and mucosal scrapings were collected for extraction of RNA. RNA from LPS-treated (n ≥ 3) and PBS-treated (n ≥ 3) control human gut xenografts and mouse jejunum were purified using GenElute Mammalian Total RNA kit (Sigma) following manufacturer's instructions, and RNA samples were The read quality of all samples were assessed separately using FASTQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) and raw reads were preprocessed using Cutadapt (19) to remove adapter and low quality sequences. The paired end reads were aligned using TopHat 2.0.14 to a reference genome that consisted of the combination of the reference genomes GRCh38 (human, Ensembl release 83) and GRCm38 (mouse, Ensembl release 83), modifying the chromosome names in order to identify the two species. The alignments for the two species were then separated with the original chromosome names restored. HTSeq-count 0.6.1p1 was then used to produce read counts for each gene based on the reference annotations Homo_sapiens.GRCh38.80.gtf and genes_mm10_ens.gtf. Adjusted log2 fold change and adjusted p-values (corrected for multiple tests) were calculated using DESeq2 (56) to determine significant differences in gene expression. Genes were scored according to an absolute fold-change ≥ 1 and adjusted p-value of < 0.05. The Ensembl Biomart (57) was used to extract all orthologous mouse genes for all genes in the human genome GRCh38 (release 83). The result was a list of orthologs with a one-to-one, one-to-many or many-to-many relationship with the human gene, and also a binary confidence value for each ortholog. To select the best match ortholog for each human gene the following procedure was followed. All one-to-one orthologs were selected and retained. For one-to-many and manyto-many orthologs, where there was only one high confidence ortholog (confidence = 1) this was selected. If there was greater than one or no high confidence orthologs the ortholog with the highest percentage identity with the mouse gene was selected, else if the percentage identity was the same for each ortholog the ortholog with the matching gene name was selected and retained. This combined list resulting from this procedure consisted of 18,719 murine orthologs. To keep the text concise and readable we use uppercase HGNC gene names throughout when referring to orthologs in both human and mouse. GSEA was performed using the using the fgsea package (version 1.2.2) in R (29) . The ImmuneSigDB Gene Sets (c7.all.v6.1.symbols.gmt) were downloaded from the Broad Institute website respectively. Genes with log2FC values >0 were more highly expressed in LPStreated gut relative to PBS-treated gut, and genes with log2FC values < 0 were more highly expressed in PBS-treated gut relative to LPS-treated gut. Scatter plots and Pearson's correlation coefficient R 2 of significantly expressed gene changes (P < 0.05; |FC| >1) in response to LPS treatment in either human or mouse gut. Non-significant FC were assigned the value of 1 (log2 = 0) and are located on the y-axis (for non-significant human genes) or on the x-axis (for nonsignificant mouse genes). respectively. Genes with log2FC values > 0 were more highly expressed in LPStreated gut relative to PBS-treated gut, and genes with log2FC values < 0 were more highly expressed in PBS-treated gut relative to LPS-treated gut. Scatter plots and non-parametric Spearman rank correlation coefficient ρ of gene changes significantly expressed (P < 0.05; |FC| >1) in response to LPS treatment in both human or mouse gut. respectively. For comparison of parametric and non-parametric data, t-test and non-parametric Mann-Whitney two-independent-samples test (respectively) were applied using GraphPad Prism 6 (GraphPad Software, Inc.). A P value of 0.05 or less was considered significant. A; mean score (*, P < 0.05) significantly different compared to time point 0. Mucosal immune responses in COVID19 -a living review Enhancing host cell infection by SARS-CoV-2 SARS-CoV-2 and COVID-19 Pathway (Homo sapiens) Interplay May Be the Main Risk Factor for COVID-19 Stevens BR (2020) TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney ADAM17 inhibition may exert a protective effect on COVID-19 Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice Genomic responses in mouse models poorly mimic human inflammatory diseases Genomic responses in mouse models greatly mimic human inflammatory diseases Of mice, men, and inflammation Genomic responses to inflammation in mouse models mimic humans: We concur, apples to oranges comparisons won't do Human intestine matures as nude mouse xenograft Xenotransplantation of human intestine into mouse abdomen or subcutaneous tissue: Novel platforms for the study of the human enteric nervous system Enterohemorrhagic Escherichia coli induce attaching and effacing lesions and hemorrhagic colitis in human and bovine intestinal xenograft models Mycobacterium avium paratuberculosis invades human smallintestinal goblet cells and elicits inflammation T3SS-dependent microvascular thrombosis and ischemic enteritis in human gut xenografts infected with enteropathogenic Escherichia coli Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor-alpha Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas NF-kappa-B activation unveils the presence of inflammatory hotspots in human gut xenografts. bioRxiv:2020 A network-based analysis of systemic inflammation in humans RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide The orchestrated cellular and molecular responses of the kidney to endotoxin define a precise sepsis timeline Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation Molecular signatures database (MSigDB) 3.0 IFITM Genes, Variants, and Their Roles in the Control and Pathogenesis of Viral Infections Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications COVID-19: immunopathology and its implications for therapy Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper Viral evasion and subversion of pattern-recognition receptor signalling IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function Commensal viruses maintain intestinal intraepithelial lymphocytes via noncanonical RIG-I signaling Enteric Viruses Ameliorate Gut Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated Interferon-beta Production IFN-I and IL-22 mediate protective effects of intestinal viral infection Nucleic Acid Induced Interferon and Inflammasome Responses in Regulating Host Defense to Gastrointestinal Viruses 2020) Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19 Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling Interplay between SARS-CoV-2 and the type I interferon response Precision mouse models with expanded tropism for human pathogens SARS-CoV-2 productively infects human gut enterocytes Developmental regulation of intestinal epithelial hydrolase activity in human fetal jejunal xenografts maintained in severecombined immunodeficient mice Human intestinal development in a severe-combined immunodeficient xenograft model Study of viral pathogenesis in humanized mice Memory CD4+ T cells are generated in the human fetal intestine Mass cytometry reveals innate lymphoid cell differentiation pathways in the human fetal intestine Human Fetal TNF-α-Cytokine-Producing CD4+ Effector Memory T Cells Promote Intestinal Development and Mediate Inflammation Early in Life Maturation of the Human Intestinal Immune System Occurs Early in Fetal Development Nos3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 Ensembl BioMarts: a hub for data retrieval across taxonomic space GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists